Analytical & Advisory Services Division

Pharmaceutical Quality and Investigation Section

About the Section

The Section was established on 3 May 2010 under the Other Scientific Service Group of Analytical and Advisory Division. Its major activities are to perform safety evaluation of pharmaceutical items, including proprietary Chinese medicines, on sale in the market for western medicines adulteration and coordinate urgent services to the Department of Health for drug’s related incidents.

Pharmaceutical Items

Pharmaceutical Items

Responsibilities

The Section will centralize all routine analytical works related to western medicines adulteration of proprietary Chinese medicines and other proprietary herbal medicines. The Section will also provide necessary analytical, investigatory and enforcement support to the Department of Health (DH) for urgent suspected poisoning cases concerning the consumption of products containing undeclared western drug ingredients. The Senior Chemist of the Section with the support from the Chemists of the Section will be the first contact point for drug’s related emergency incidents.

Quality Assurance

About 10% of the tests conducted in the Section are for QC purposes.

Key Instruments

The following instruments are used routinely by the Section:

  • High Performance Liquid Chromatograph — Tandem Mass Spectrometer
  • High Performance Liquid Chromatograph — Quadrupole Time of Flight Mass Spectrometer
HPLC-QTOF

HPLC-QTOF

Targets and Key Indicators

Working closely with the Chinese Medicines Section and the Pharmaceutical Chemistry Section, the Key Performance Measures Relating to the Statutory Testing of Chinese Medicines and Pharmaceuticals are:

Key Performance Measures Relating to the Statutory Testing of Chinese Medicines and Pharmaceuticals

Targets #
Targets 2022 (Actual) 2023 (Actual) 2024 (Plan)
95 100 100 95

Targets 2022 (Actual) 2023 (Actual) 2024 (Plan)
95 99 99 95

Targets 2022 (Actual) 2023 (Actual) 2024 (Plan)
95 100 100 95

Targets 2022 (Actual) 2023 (Actual) 2024 (Plan)
95 98 99 95

#  For targets where reporting time is mentioned, different samples require different analytical procedures, hence different reporting time. The quoted number of working days required represents an average of reporting time for the different types of samples and test requests within the category, while the target (in percentage) is the total compliance rate of the concerned samples and test requests within a particular category against their respective targets.

Key Indicators
Tests Performed on Chinese Medicines
and Pharmaceuticals
2022 (Actual) 2023 (Actual) 2024 (Estimate)
Urgent samples relating to
Chinese medicine incidents
44 30 N.A.
Other Chinese medicine samples 82,612 86,133 86,000
Urgent samples relating to
pharmaceutical incidents
10 106 N.A.
Other pharmaceutical samples 52,099 52,575 51,000

‡ As the testing requirements for urgent samples relating to food, pharmaceuticals and Chinese medicine incidents respectively fluctuated in previous years, it is difficult to estimate the occurrence of the type of incidents or the number of tests required.